Skip To Main Content
A. Barzi on Muck Rack

A. Barzi

As seen in: Annals of Oncology, Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with A.

Contact A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multimodality treatment (MMT) and outcomes of gastric adenocarcinoma (GC) in National Cancer DataBase(NCDB)

|
By A. Barzi, Los Angeles, D. -H. Yang, H-J. Lenz
| Annals of Oncology Verified
Background: In patients (pts) with non-metastatic GC, MMT added to surgery improves the cure rate. The MMT includes adjuvant chemoradiation (ACR), neoadjuvant chemoradiation (NACR), and perioperative chemotherapy (CT). We used the NCDB data to compare different MMT in pts with non-metastatic GC. Methods: A total of 79369 pts with non-metastatic GC diagnosed 2004- 2013 were identified. Pts with known tumor site who underwent surgery and received MMT were selected for this analysis.
Open in Who Shared Issue with article?

Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer

|
By A. Barzi, Los Angeles, I. Chau, S-E. Al-Batran
| Annals of Oncology Verified
Background: Association of radiological tumor status (TS; progressed vs non-progressed) and QoL has not been systematically explored in randomized clinical trials (RCTs) of gastroesophageal cancers. Furthermore, TS is affected by disease measurability (DM) as defined by RECIST. We explored these factors using data from two phase 3 RCTs of previously treated gastric or GEJ cancer: RAINBOW (ramucirumab + paclitaxel vs placebo + paclitaxel) and REGARD (ramucirumab vs placebo).
Open in Who Shared Issue with article?

Comparative Effectiveness of Panitumumab Versus Cetuximab In Patients With Chemo-Refractory Wild-Type Kras Metastatic Colorectal Cancer

|
By Y. L. Xu, J. W. Hay, A. Barzi
| Value in Health Journal Verified
In the recent head-to-head ASPECCT trial, P and C showed similar effectiveness, though their administration and toxicity are different. This study aims to evaluate the comparative effectiveness of P and C as monotherapy in chemo-refractory mCRC with WT KRAS from a U.S. societal perspective.
Open in Who Shared Issue with article?
See all 3 articles